Xtandi Sales Disappoint Pfizer, Returning Focus To The High-Priced Deal

Xtandi sales declined 11% in the first quarter due to an increase in the use of patient assistance programs, but demand grew 13%, which management said reflects the underlying strength of the prostate cancer drug.